icone plus
Contact
Abonnez-vous aux actualités
Autorisation d’accès précoce refusée à la spécialité TABRECTA (capmatinib).
Voir aussi
Décision d'accès précoce
05/08/2022
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
neGYMdFVu1qKR7m9